Stay updated with breaking news from Subadra dravida. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Stepping up stem cell research biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.
Hyderabad varsity startup develops stem cell-based treatment for Covid Top Searches: IANS | Updated: May 4, 2021, 09:46 IST A biotech startup company, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), on Monday announced a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy for Covid patients. Picture used for representational purpose only HYDERABAD: A biotech startup company, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), on Monday announced a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy for Covid patients. Transcell Oncologics has developed a proprietary cell-based platform technology, HEMATO UC-MSCs, with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities. ....
Significantly improved patient survival and time to recovery observed following the treatment, says Transcell Oncologics A breakthrough human Umbilical Cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs)-based therapy to COVID patients has been announced by Transcell Oncologics, a biotech start-up company, incubated at ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH) on Monday. The firm had developed proprietary cell-based platform technology ‘HEMATO UC-MSCs’ with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities. The research recommends HEMATO UC-MSCs to be administered as “two intravenous infusions, at a dose of 100 million cells per infusion, given 72 hours apart to the COVID patients. ....
Hyderabad-based Startup Develops Stem Cell Therapy for COVID by Angela Mohan on May 4, 2021 at 9:45 AM Adult Mesenchymal Stem Cells (MSCs)-based therapy may hold potential in treating COVID-19 positive patients. Transcell Oncologics has developed a proprietary cell-based platform technology, HEMATO UC-MSCs, with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities. The treatment is associated with a significant decrease in a set of inflammatory cytokines involved in the COVID-19 cytokine storm , with significantly improved patient survival and time to recovery. The research recommends HEMATO UC-MSCs to be administered as two intravenous infusions, at a dose of 100 million cells per infusion, given 72 hours apart to the COVID patients . ....
New stem cell-based therapy by University of Hyderabad startup may speed up COVID recovery The research conducted on HEMATO UC-MSCs recommends that it must be administered as two intravenous infusions, at a dose of 100 million cells per infusion, given 72 hours apart . Share Via Email | A+A A- By Express News Service HYDERABAD: A biotech startup incubated at the University of Hyderabad (UoH) has developed a new stem cell-based therapy for the treatment of COVID-19 patients. The therapy been found to significantly reduce the cytokine storm with improved patient survival and time of recovery. The new therapy is based on Umbilical Cord (UC) tissue-harvested and clinically processed adult Mesenchymal Stem Cells (MSCs). The therapy, developed by Transcell Oncologics, has already been used as part of the treatment regimen by doctors treating Covid-19 patients in a few hospitals across Hyderabad, Warangal and Delhi. ....